Palisade bio (nasdaq: pali) receives fda “study may proceed” letter for pivotal phase 3 clinical trial evaluating lb1148 to accelerate the return of bowel function following abdominal surgery

Carlsbad, calif., march 22, 2022 (globe newswire) -- palisade bio, inc. (nasdaq: pali), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (gi) complications, announced that the company received a “study may proceed” letter from the u.s. food and drug administration (fda) for a phase 3 clinical trial to evaluate lb1148 to accelerate the return of bowel function in adult patients undergoing bowel/abdominal surgery.
PALI Ratings Summary
PALI Quant Ranking